Artelo Biosciences (ARTL) to Post Quarterly Earnings on Wednesday

Artelo Biosciences (NASDAQ:ARTL) will likely be announcing its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect the company to announce earnings of ($0.72) per share for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 4:00 PM ET.

Artelo Biosciences (NASDAQ:ARTL) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($4.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($3.22).

Artelo Biosciences Stock Up 3.0%

ARTL opened at $0.77 on Wednesday. Artelo Biosciences has a 52 week low of $0.71 and a 52 week high of $31.65. The business has a 50 day moving average price of $1.15 and a two-hundred day moving average price of $3.27. The company has a market cap of $1.78 million, a PE ratio of -0.02 and a beta of -0.07.

Analyst Ratings Changes

ARTL has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Artelo Biosciences in a report on Wednesday, June 24th. Wall Street Zen raised Artelo Biosciences from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average price target of $54.00.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes.

The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia.